Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus
Open Access
- 31 August 2004
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 191 (2) , 558-562
- https://doi.org/10.1016/j.ajog.2004.01.034
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant womenAIDS, 2003
- Pre-eclampsia, antiretroviral therapy, and immune reconstitutionThe Lancet, 2002
- Concentrations of protease inhibitors in cord blood after in utero exposureThe Pediatric Infectious Disease Journal, 2002
- Protease Inhibitors and Decreased Birth Weight in HIV-Infected Pregnant Women With Impaired Glucose ToleranceJournal of Perinatology, 2002
- Pharmacokinetics of Saquinavir-SGC in HIV-Infected Pregnant WomenHIV Research & Clinical Practice, 2001
- Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral ActivitiesAntimicrobial Agents and Chemotherapy, 2001
- An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancyAIDS, 2001
- Combination antiretroviral therapy and duration of pregnancyAIDS, 2000
- Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus‐infected patients with chronic liver diseaseBritish Journal of Clinical Pharmacology, 2000
- Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposureJournal of Clinical Investigation, 1999